Kong Yiu Cheung Acquires 222,223 Shares of NewGenIvf Group (NASDAQ:NIVF) Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 222,223 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $333,334.50. Following the completion of the acquisition, the director directly owned 222,223 shares of the company’s stock, valued at $333,334.50. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The shares were acquired at an average price of $1.00 per share, with a total value of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung bought 500,000 shares of NewGenIvf Group stock. The shares were bought at an average cost of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Trading Down 2.5%

NASDAQ:NIVF opened at $1.18 on Friday. NewGenIvf Group Limited has a fifty-two week low of $1.11 and a fifty-two week high of $1,539.00. The company has a 50 day moving average price of $2.79 and a 200 day moving average price of $10.97. The company has a quick ratio of 2.98, a current ratio of 3.12 and a debt-to-equity ratio of 0.16.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. Wall Street Zen upgraded shares of NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, NewGenIvf Group has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.